ERBB2 and triple-negative breast carcinoma: The proportion of trials in HER2-positive and triple-negative breast cancer has increased in parallel, probably explaining the trend regarding allowance for BM; however, there have been very few BM-specific trials, and efforts are needed to increase their number.